Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Pfizer
iOnctura
Merck Sharp & Dohme LLC
University of California, Davis
Hoffmann-La Roche
University Health Network, Toronto
Children's Oncology Group
BioInvent International AB
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
NuCana plc
OncoNano Medicine, Inc.
Mayo Clinic
Compass Therapeutics
National Cancer Institute (NCI)
Miltenyi Biomedicine GmbH
Cancer Research UK
Cancer Research UK
GlaxoSmithKline
UNC Lineberger Comprehensive Cancer Center
Arcus Biosciences, Inc.
Incyte Corporation
Novartis
Shattuck Labs, Inc.
GlaxoSmithKline
Seagen Inc.
National Cancer Institute (NCI)
Checkpoint Therapeutics, Inc.
Vector Vitale LLC
National Cancer Institute (NCI)
Cedars-Sinai Medical Center
Presage Biosciences
Celldex Therapeutics
Eisai Inc.
TopAlliance Biosciences
Stanford University
Deciphera Pharmaceuticals, LLC
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
Hoffmann-La Roche
NovalGen Ltd.
Seagen Inc.
Fate Therapeutics
Sierra Oncology LLC - a GSK company
Pfizer
Bristol-Myers Squibb